NEW POSSIBILITIES OF STATIN THERAPY IN ARTERIAL HYPERTENSION

Background. Effects of statins on cardiovascular end points are well-known. To study the impact of statins on structural and functional heart remodeling in patients with arterial hypertension (HT) seems

to be topical.

Aim. To study the effect of statins on cardiac remodeling in patients with HT.

Materials and methods. 120 patients with HT of 1 degree were included into the study: 56 men, 64 women, aged 52.4±10.23. Patients were randomized into 4 treatment groups: Group A1 (angiotensin converting enzyme (ACE) inhibitors + diet), group A2 (ACE inhibitor + fluvastatin), group B1 (angiotensin II receptor antagonist (ARA II) + diet), group B2 (ARAII + fluvastatin). Transthoracic echocardiography with calculation of standard left ventricle (LV) remodeling indices was performed.

Results. The most important prognostic markers of LV remodeling were revealed. They were a basis for definition of 3 types of early LV remodeling: type 1 — compensated, type 2 — adaptive, 3 type — maladaptive. After 6 months of treatment a number of patients in group A1 with type 2 and type 3 of LV remodeling reduced less (2%, p=0.02 and 4%, p=0.04, respectively) than this in group A2 (14%, p=0.04) and 4%, p=0.04, respectively). A number of patients with type 1 (compensated) of LV remodeling increased by 18% (p<0.001) in group A2, and by 6%, (p=0.03) in group A1. After the treatment a number of patients with type 3 and type 2 of LV remodeling decreased (p<0.001 and p=0.04, respectively) in groups B1 and B2 while a number of patients with type 1 of LV remodeling increased (p<0,001). A number of patients with type 1 of LV remodeling increased and this with type 3 of LV remodeling decreased in group B2 more prominently in comparison with group A2 (p=0.03; p=0.01, respectively).

Conclusion. Statins in patients with HT have cardioprotective effect that does not depend on basic antihypertensive therapy and total cholesterol level. In these patients combination of statins with ARA II has better cardioprotective effect than this with ACE inhibitors.

1. Aronov D.M. Profilaktika i lechenie ateroskleroza. M.: Triada-X; 2000. Russian (АроновД.М. Профилактика и лечение атеросклероза. М.: Триада-Х; 2000).

2. Dupuis J., TardifJ.C., Cernacek P., Théroux P. Cholesterolreduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999;99(25):3227-33.

3. Buchwald H., Varco R.L., Matts J.P. et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990;323(14):946-55.

4. Halcox J.P., Deanfield J.E. Beyond the laboratory: clinical implications for statin pleiotropy / J.P. Halcox, J.E. Deanfield. Circulation 2004;109(21 Suppl 1):II42-8.

5. Law M., Wald N.J. Efficacy and safety of cholesterol–lowering treatment. Lancet 2006;367(9509):469-70.

6. Gao L., Wang W., Li Y.L. et al. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005;112(12):1763-70.

7. Kannel W.B. Left ventricular hypertrophy by Electrocardiogram: prevalence, incidence and mortality in the Framingham Heart Study / W.B. Kannel, I. Gordon, D. Offett // Ann Intern Med. – 1969. – Vol. 71. – Р. 89-112.

8. Crisby M. Modulation of the inflammatory process by statins. Timely Top Med Cardiovasc Dis 2005;9:E3.

9. Mogensen C.E., Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321(7274):1440-4.

10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) / Scandinavian Simvastatin Survival Study Group. Lancet 1994;344(8934):1383-9.

11. Brunner H.R. Experimental and clinical evidence that angiotensin II is an independent risk factor for cardiovascular disease. Am J Cardiol 2001;87(8A):3C-9C.

12. Teplova N.V. Clinical efficacy of angiotensin converting enzyme inhibitors in the treatment of hypertension. Russkiy meditsinskiy zhurnal 2004; 12(9): 523-527. Russian (Теплова Н.В. Клиническая эффективность ингибиторов ангиотензин-превращающего фермента в лечении артериальной гипертензии. Русский медицинский журнал 2004; 12(9): 523-527).

13. National guidelines for diagnosis and treatment of hypertension. Kardiovaskulyarnaya terapiya i profilaktika 2008; 7(6) suppl 2:1-32. Russian (Национальные рекомендации по диагностике и лечению артериальной гипертонии. Кардиоваскулярная терапия и профилактика 2008; 7(6) Приложение 2:1-32).

14. Rogoza A.N. Ambulatory blood pressure monitoring. Serdtse 2002;1(5):240-242. Russian (Рогоза А.Н. Суточное мониторирование артериального давления. Сердце 2002;1(5):240-242).

15. Cheitlin M.D., Alpert J.S., Armstrong W.F. et al. ACC/AHA Guidelines for the Clinical Application of Echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in collaboration with the American Society of Echocardiography. Circulation 1997;95(6):1686-744.

16. Devereux R.B., Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation 1977;55(4):613-8.

17. de Simone G., Daniels S.R., Devereux R.B. et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992;20(5):1251-60.

18. Belenkov Yu.N., Mareev V.Yu., Orlova Ya.A. Magnetic resonance imaging in the evaluation of left ventricular remodeling in patients with heart failure. Kardiologiia 1996;4:15 - 23. Russian (Беленков Ю.Н., Мареев В.Ю., Орлова Я.А. Магнитно-резонансная томография в оценке ремоделирования левого желудочка у больных с сердечной недостаточностью. Кардиология 1996;4:15 – 23).

19. Vasyuk Yu.A. Capabilities and limitations of echocardiography in the assessment ofleft ventricular remodeling in CHF. Serdechnaya nedostatochnost' 2003;4(2):107– 110. Russian (Васюк Ю.А. Возможности и ограничения эхокардиографического исследования в оценке ремоделирования левого желудочка при ХСН. Сердечная недостаточность 2003;4(2):107– 110).

20. Kuznetsov G.E. Evaluation of left ventricular function with position changes to its geometry in patients with heart failure against a background of coronary heart disease. Serdechnaya nedostatochnost' 2002;3(6):292-294. Russian (Кузнецов Г.Э. Оценка функции левого желудочка с позиции изменений его геометрии у больных сердечной недостаточностью на фоне ишемической болезни сердца. Сердечная недостаточность 2002;3(6):292-294).

21. Störk T.V., Müller R.M., Piske G.J. et al. Noninvasive measurement of left ventricular filling pressures by means of transmitral pulsed Doppler ultrasound. Am J Cardiol 1989;64(10):655-60..

22. Sorrentino S., Landmesser U. Nonlipid–lowering Effects of Statins. Curr Treat Options Cardiovasc Med 2005;7(6):459-66.

23. Ashida T. Treatment of hypertension with dyslipidemia. Nippon Rinsho 2001;59(5): 978-82.

24. Schwartz J.S., McLaughlin T., Griffis D. et al. Adherence to chronic therapy among patients treated for hypertension, dyslipidemia, or both. Abstracts of 52th Annual Scientific Session of American College of cardiology. Chicago: ACC; 2003. P. 1.

25. Pitt B. Potential role of angiotensin–converting enzyme inhibitors in the treatment of atherosclerosis. Eur Heart J 1995;16 Suppl K:49-54.

26. Chapman R.H, Benner J.S., Petrilla A.A et al. Adherence with concomitant antihypertensive and lipid–lowering therapy. Abstarcs of 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; 2004. Р.2.

27. Bauersachs J., Galuppo P., Fraccarollo D. et al. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase ingibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 2001;104(9): 982-5.

28. Bastiaanse E.M., Atsma D.E., Kuijpers M.M. et al. Simvastatin-sodium delays cell death of anoxic cardiomyocytes by inhibition of the Na+/Ca2+ exchanger. FEBS Lett 1994;343(2):151-4.